Updated: June 16, 2026 CET Updated: June 16, 2026 CET Updated: April 08, 2025 CET Updated: June 16, 2026 CET Updated: May 19, 2025 CET
The Upcoming PCAC Meeting The FDA notice confirms that the PCAC will convene this summer to evaluate whether to recommend the following seven bulk drug substances for inclusion on the 503A bulks list: July 23, 2026: BPC-157 (free base / acetate) KPV (free base / acetate) Thymosin Beta-4, Fragment (LKKTETQ) (TB-500) (free base / acetate) MOTs-C (free base / acetate) July 24, 2026: Emideltide (DSIP) (free base / acetate) Semax (free base / acetate) Epitalon (free base / acetate) All seven substances are of considerable interest to compounding pharmacies, prescribers, and patients
Clinical data paints a clearer picture of what users can realistically expect
(1965) [Aphonia of late onset due to occupational exposure to ethylene oxide.] Med
Learning about vitamin B12 therapy helps us support patients better
What concentration of GHK-Cu works